| scholarly article | Q13442814 |
| P50 | author | Francis V. Chisari | Q1424562 |
| Paul Targett-Adams | Q29460024 | ||
| Craig E. Cameron | Q74809374 | ||
| P2093 | author name string | Michael D Bobardt | |
| Philippe A Gallay | |||
| Udayan Chatterji | |||
| Tanya Parkinson | |||
| Stefan Wieland | |||
| Precious Lim | |||
| Daniel G Cordek | |||
| Gregoire Vuagniaux | |||
| P2860 | cites work | Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase | Q24306483 |
| Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors | Q24645702 | ||
| Diverse Effects of Cyclosporine on Hepatitis C Virus Strain Replication | Q27473218 | ||
| NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon | Q27477455 | ||
| Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro | Q27486118 | ||
| Combinations of Cyclophilin Inhibitor NIM811 with Hepatitis C Virus NS3-4A Protease or NS5B Polymerase Inhibitors Enhance Antiviral Activity and Suppress the Emergence of Resistance | Q27486821 | ||
| Hepatitis C Virus NS5A Protein Is a Substrate for the Peptidyl-prolyl cis/trans Isomerase Activity of Cyclophilins A and B | Q27488369 | ||
| Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex | Q27488788 | ||
| Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics | Q27489037 | ||
| The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication | Q27489053 | ||
| SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro | Q27490844 | ||
| The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro | Q34504825 | ||
| Therapy of hepatitis C: from empiricism to eradication | Q36382235 | ||
| Antiviral therapy for chronic hepatitis C: past, present, and future | Q36406543 | ||
| Cyclophilin inhibitors | Q37560260 | ||
| Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition | Q38326418 | ||
| HCV genotype 1b chimeric replicon with NS5B of JFH-1 exhibited resistance to cyclosporine A. | Q39795443 | ||
| Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor | Q39816111 | ||
| Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. | Q40113778 | ||
| Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins | Q40376973 | ||
| Purification and characterization of hepatitis C virus non-structural protein 5A expressed in Escherichia coli | Q40528507 | ||
| Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes | Q40622941 | ||
| Host cyclophilin A mediates HIV-1 attachment to target cells via heparans | Q40914592 | ||
| Effects of cyclosporin A on hepatitis C virus infection in bone marrow transplant patients. Bone Marrow Transplantation Team | Q42986133 | ||
| Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. | Q42999156 | ||
| The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. | Q43046668 | ||
| Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial | Q43047961 | ||
| Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease | Q45474964 | ||
| The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. | Q48033815 | ||
| P433 | issue | 1 | |
| P921 | main subject | cyclosporine | Q367700 |
| P304 | page(s) | 50-56 | |
| P577 | publication date | 2010-04-03 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors | |
| P478 | volume | 53 |
| Q39394432 | A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility |
| Q28743482 | An integrated transcriptomic and meta-analysis of hepatoma cells reveals factors that influence susceptibility to HCV infection |
| Q33565080 | Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells |
| Q26771251 | Chaperones in hepatitis C virus infection |
| Q28551538 | Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175 |
| Q34489239 | Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. |
| Q42013717 | Correlation between NS5A dimerization and hepatitis C virus replication |
| Q36993953 | Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms |
| Q38131681 | Current and future therapies for hepatitis C virus infection: from viral proteins to host targets |
| Q37297666 | Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus-induced Hepatocellular Carcinoma |
| Q42780244 | Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner |
| Q39747173 | Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes |
| Q27468931 | Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection |
| Q35385005 | Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories |
| Q38615621 | Cyclophilin inhibitors as a novel HCV therapy |
| Q42284188 | Cyclophilin inhibitors as antiviral agents |
| Q39244702 | Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis |
| Q37968485 | Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents |
| Q38064282 | Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection |
| Q38040256 | Cyclophilin involvement in the replication of hepatitis C virus and other viruses. |
| Q38121470 | Cyclophilins as modulators of viral replication |
| Q28483731 | Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways |
| Q35960586 | Cyclosporin A inhibits the replication of diverse coronaviruses |
| Q28748683 | DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A |
| Q39063756 | Deep sequencing in the management of hepatitis virus infections. |
| Q37962197 | Diabetes mellitus following liver transplantation in patients with hepatitis C virus: risks and consequences |
| Q64058174 | Differences across cyclophilin A orthologs contribute to the host range restriction of hepatitis C virus |
| Q37835939 | Emerging picture of host chaperone and cyclophilin roles in RNA virus replication. |
| Q38848095 | Entangled in a membranous web: ER and lipid droplet reorganization during hepatitis C virus infection |
| Q34075689 | Ethanol and reactive species increase basal sequence heterogeneity of hepatitis C virus and produce variants with reduced susceptibility to antivirals. |
| Q42068187 | HCV NS5A and IRF9 compete for CypA binding |
| Q56396163 | HCV NS5A dimer interface residues regulate HCV replication by controlling its self-interaction, hyperphosphorylation, subcellular localization and interaction with cyclophilin A |
| Q28539751 | HCV core residues critical for infectivity are also involved in core-NS5A complex formation |
| Q34332546 | Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance |
| Q45373310 | Hepatitis C virus nonstructural protein 5A inhibitors: Novel target-Now for new trials and new treatment strategies |
| Q37676364 | Host-targeting agents in the treatment of hepatitis C: a beginning and an end? |
| Q58546274 | Human MxB inhibits the replication of HCV |
| Q43039673 | Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection |
| Q28364857 | Infection Counter: Automated Quantification of in Vitro Virus Replication by Fluorescence Microscopy |
| Q64257927 | Inhibitor of Sarco/Endoplasmic Reticulum Calcium-ATPase Impairs Multiple Steps of Paramyxovirus Replication |
| Q35400246 | Inhibitors of peptidyl proline isomerases as antivirals in hepatitis C and other viruses |
| Q41488466 | Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication |
| Q37812189 | Mixing the right hepatitis C inhibitor cocktail |
| Q42246268 | Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients |
| Q39313413 | Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir |
| Q35653358 | New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy |
| Q37972755 | New targets for antiviral therapy of chronic hepatitis C. |
| Q90669855 | Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C |
| Q98243761 | PCV2 inhibits the Wnt signalling pathway in vivo and in vitro |
| Q33934864 | Peptidyl-prolyl isomerase Pin1 is a cellular factor required for hepatitis C virus propagation |
| Q37144087 | Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibility |
| Q39579921 | Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family |
| Q34329744 | Profile of alisporivir and its potential in the treatment of hepatitis C. |
| Q56957250 | Quasispecies and Drug Resistance |
| Q26777408 | Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications |
| Q38174301 | Revisiting dengue virus-host cell interaction: new insights into molecular and cellular virology |
| Q39206099 | Subtype specific differences in NS5A domain II reveals involvement of proline at position 310 in cyclosporine susceptibility of hepatitis C virus |
| Q37006634 | The C terminus of NS5A domain II is a key determinant of hepatitis C virus genome replication, but is not required for virion assembly and release |
| Q35742761 | The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action |
| Q64916774 | The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice. |
| Q41843629 | The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes |
| Q38274889 | The role of immunophilins in viral infection |
| Q26740219 | Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance |
| Q42977561 | Update on alisporivir in treatment of viral hepatitis C. |
| Q27013917 | Viral quasispecies evolution |
Search more.